In addition, three glucose metabolism-related genes (SERPINE1, VCAN, and TFPI2) may be potential targets for the immunotherapy of patients with NAFLD-hepatocellular carcinoma. This evidence concerns the gene VCAN and metabolic dysfunction-associated steatotic liver disease.